Zafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additiona...
July 02 2018 - 4:05PM
Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical
company leveraging its proprietary MetAP2 biology platform to
develop novel therapies for patients affected by complex metabolic
diseases, today announced the closing of its previously announced
registered underwritten public offering of 9,200,000 shares of its
common stock at a price to the public of $7.50 per share, including
1,200,000 common shares sold pursuant to the underwriters’ exercise
in full of their option to purchase additional common shares.
The offering resulted in total gross proceeds of $69.0 million,
before deducting the underwriting discounts and commissions and
other estimated offering expenses. All of the shares in the
offering were sold by Zafgen.
Cowen and Company, LLC and Piper Jaffray & Co. served as
joint book-running managers for the offering, and JMP Securities
LLC and Wedbush Securities Inc. served as co-lead managers.
The shares were offered by Zafgen pursuant to a shelf
registration statement that was previously filed with, and
subsequently declared effective by, the Securities and Exchange
Commission (SEC). A prospectus supplement relating to and
describing the terms of the offering was filed with the SEC and
available on the SEC’s website at www.sec.gov. Copies of the final
prospectus relating to the offering may be obtained by contacting
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY, 11717, Attn: Broadridge Financial
Solutions, by telephone at (631) 274-2806, or Piper Jaffray &
Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email
at prospectus@pjc.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About ZafgenZafgen (Nasdaq:ZFGN) is a
clinical-stage biopharmaceutical company leveraging its proprietary
MetAP2 biology platform to develop novel therapies for patients
affected by complex metabolic diseases. Zafgen has pioneered the
study of MetAP2 inhibitors in both common and rare metabolic
disorders and is currently advancing programs for type 2 diabetes,
Prader-Willi syndrome and liver diseases. The Company’s lead
product candidate, ZGN-1061, a MetAP2 inhibitor for
difficult-to-control type 2 diabetes, has successfully completed
the initial part of a Phase 2 clinical trial. Learn more at
www.zafgen.com.
Media/Investor Relations
Contacts: Zafgen, Inc. Patricia Allen
Chief Financial Officer 617-648-9792
Media Krystle Gibbs Ten Bridge Communications
krystle@tenbridgecommunications.com 508-479-6358
Investors John Woolford Westwicke Partners
John.woolford@westwicke.com 443-213-0506
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Sep 2023 to Sep 2024